Harriet Kluger, MD, associate professor of medicine, Yale Cancer Center, discusses the results from a phase I trial of nivolumab and ipilimumab for the treatment of patients with advanced melanoma.
The overall response rate of patients on the trial was over 40%, Kluger says, while one- and two- year overall survival rates were 85% and 79%, respectively. This type of survival has never been seen before in metastatic melanoma.
Kluger notes that many patients had a poor prognosis prior to the trial – many had elevated LDH and 53% of patients were M1c.
<<< View more from the 2014 ESMO Congress